- ExpreS2ion Biotech Holding AB has selected Northway Biotech as its cGMP CDMO for a Nipah virus vaccine candidate under an EU-funded Horizon Europe project.
- Manufacturing is planned to begin in Q1 2026 and target completion by the end of 2026.
ExpreS2ion Biotech Holding AB, through its affiliate ExpreS2ion Biotechnologies ApS, has selected Northway Biotech as its contract development and manufacturing organization for a Nipah virus vaccine candidate. The program is part of an EU-funded Horizon Europe consortium addressing a pathogen with epidemic potential and recent outbreaks in South Asia.
Nipah virus is a zoonotic pathogen classified by the World Health Organization as a priority disease due to high fatality rates and the absence of approved vaccines or specific treatments. Recent confirmed cases in India have prompted containment measures and heightened regional health screening.
Northway Biotech was chosen based on its prior experience with ExpreS2ion’s recombinant protein vaccine platform, including execution of a closely related program within defined timelines. The companies have an established working relationship across development, manufacturing, and quality functions. Manufacturing activities are planned to commence in Q1 2026 and conclude by the end of 2026, supporting preparation for cGMP manufacture and subsequent development steps.
“The re-emergence of Nipah outbreaks highlights the ongoing risk posed by this virus and the importance of advancing vaccine preparedness.”
Bent U. Frandsen, Chief Executive Officer of ExpreS2ion
The CDMO selection represents a key operational milestone for ExpreS2ion’s vaccine portfolio, leveraging its ExpreS2 platform across infectious disease indications. The collaboration aligns contract manufacturing capabilities with development needs to advance the Nipah vaccine candidate toward clinical readiness.
